Mark A. Lal

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O 43183, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans.

The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans.

Journal: Molecular therapy. Advances

Published: July 16, 2025

RXFP1, the relaxin receptor: Lost and found in translation.

RXFP1, the relaxin receptor: Lost and found in translation.

Journal: Drug discovery today

Published: June 18, 2025

Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists.

Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists.

Journal: Journal of medicinal chemistry

Published: March 19, 2024

Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure.

Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure.

Journal: Journal of medicinal chemistry

Published: March 19, 2024

Unraveling the role of natriuretic peptide clearance receptor (NPR3) in glomerular diseases.

Unraveling the role of natriuretic peptide clearance receptor (NPR3) in glomerular diseases.

Journal: Scientific reports

Published: November 04, 2023

APOL1 promotes endothelial cell activation beyond the glomerulus.

APOL1 promotes endothelial cell activation beyond the glomerulus.

Journal: iScience

Published: March 30, 2023

Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing.

Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing.

Journal: Kidney international

Published: December 14, 2020

Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-κB signaling pathway.

Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-κB signaling pathway.

Journal: Kidney international

Published: July 27, 2020

Single-cell RNA sequencing reveals the mesangial identity and species diversity of glomerular cell transcriptomes.

Single-cell RNA sequencing reveals the mesangial identity and species diversity of glomerular cell transcriptomes.

Journal: Nature communications

Published: December 10, 2019

GPRC5b Modulates Inflammatory Response in Glomerular Diseases via NF-κB Pathway.

GPRC5b Modulates Inflammatory Response in Glomerular Diseases via NF-κB Pathway.

Journal: Journal of the American Society of Nephrology : JASN

Published: January 28, 2019

Coro2b, a podocyte protein downregulated in human diabetic nephropathy, is involved in the development of protamine sulphate-induced foot process effacement.

Coro2b, a podocyte protein downregulated in human diabetic nephropathy, is involved in the development of protamine sulphate-induced foot process effacement.

Journal: Scientific reports

Published: November 01, 2018

Understanding Podocyte Biology to Develop Novel Kidney Therapeutics.

Understanding Podocyte Biology to Develop Novel Kidney Therapeutics.

Journal: Frontiers in endocrinology

Published: April 11, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026